VivaLNK and AMPS have partnered to advance remote patient monitoring (RPM) for clinical trials, combining AMPS’ continuous electrocardiogram (ECG) recording suite with VivaLNK medical wearable sensors to provide real-time and retrospective analysis for continuous ECG datasets in remote environments.
VivaLNK and AMPS most recently partnered for a 10-year, 3,000 subject University of California, San Francisco (UCSF) clinical trial aiming to detect biomarkers of early atrial transformation on atrial fibrillation (AF). For the study, AMPS is collecting and processing the ECG data from VivaLNK’s medical wearable sensors, which can capture ECG and heart rate on a continuous basis 24 hours a day. Each subject will wear the ECG sensor for about one week every month, while mobile or at home, and data from the sensor will then be captured through a mobile app and sent to the cloud for analysis. Continuous monitoring is particularly crucial for detecting and reporting AF, as other methods can miss an episode, providing inaccurate results.
“Our cohesive solution combined with the AMPS software application provides a winning combination for pharmaceutical companies requiring effective RPM for patient studies,” said Jiang Li, founder and CEO of VivaLNK. “We look forward to continuing this partnership and our combined uses across additional clinical trials in the years to come.”
VivaLNK’s continuous ECG platform has also been integrated with the AMPS continuous ECG recording suite, allowing for the direct analysis of recorded data.
“Our ECG analysis software has been used to measure millions of ECGs worldwide, and we take that role very seriously because of the implications it has on studies and the medical community,” said Fabio Badilini, president and chief scientist at AMPS. “The integration with VivaLNK’s medical wearable ECG sensor provides a unique solution for remote cardiac monitoring.”